PNC-27

What it is

PNC-27 is a synthetic 32-residue chimeric peptide composed of two functional domains: (1) residues 12–26 of the human p53 tumor suppressor protein, corresponding to the MDM-2 (human MDM-2, HDM-2) interaction region; and (2) a cell-penetrating leader sequence derived from penetratin (antennapedia homeodomain). The peptide's selective anti-cancer activity is mechanistically distinct from conventional apoptosis-based cancer therapeutics — it operates through necrotic membrane disruption targeting cancer cell-specific surface expression of HDM-2. The canonical mechanism involves three steps: (1) PNC-27 recognizes and binds the p53 interaction domain (residues 1–109) of HDM-2 protein expressed on the plasma membranes of cancer cells, forming 1:1 stoichiometric complexes. (2) Multiple peptide-HDM-2 complexes cluster at the membrane and form ring-shaped pore structures through which the peptide's leader sequence lines the transmembrane channel. (3) Pore formation causes rapid, necrotic cell lysis — leakage of intracellular contents and complete cell death, confirmed by LDH release assays and negative caspase activation (no apoptosis). A 2024 study additionally identified mitochondrial membrane accumulation after cellular entry, causing mitochondrial disruption — a second intracellular death mechanism. Selectivity for cancer cells over normal cells depends on differential HDM-2 membrane expression: transformed cancer cells abnormally express HDM-2 on their plasma membrane surfaces, whereas untransformed (normal) cells do not — or express it intracellularly only. This structural basis for membrane-surface HDM-2 targeting was confirmed by NMR analysis showing PNC-27 forms an S-shaped three-helical configuration in aqueous conditions and reorganizes to a U-shaped amphipathic helix-coil-helix in membrane-mimetic environments, with hydrophobic residues clustered on one face for membrane insertion. PNC-27 has demonstrated selective cytotoxicity across multiple cancer cell types including colon cancer cells (including CD44+ stem-like cells), leukemia cells (K562, p53-null), ovarian cancer cells, and pancreatic carcinoma cells (MIA-PaCa-2) (PMID 33419797, PMID 25117093, PMID 28667027, PMID 38802154). Normal cells (untransformed fibroblasts, murine lymphocytes) are spared in all reported studies. Synergistic combination with paclitaxel has been demonstrated — paclitaxel-surviving ovarian cancer cells showed upregulated surface HDM-2 and enhanced PNC-27 susceptibility.

Class: Synthetic 32-residue chimeric anticancer peptide / HDM-2 (MDM-2) binding domain fragment / membrane-targeted pro-necrotic peptide

What it's studied for

• Cancer cell killing — selective necrosis via membrane HDM-2 targeting (colon cancer, leukemia, solid tumors) In vitro only
  • PNC-27 forms 1:1 complexes with HDM-2 p53-interaction domain (residues 1–109) on cancer cell plasma membranes; ring-shaped pore structures confirmed by immuno-scanning EM. Tumor cells undergo necrotic lysis; untransformed fibroblasts unaffected. Leader sequence lines membrane pores. Conformational modeling confirmed pe PMID 35625682 Sarafraz-Yazdi E et al. Biomedicines. 2022.
  • Colon cancer stem cells (CD44+) and six colon cancer lines: all express high surface HDM-2. PNC-27 co-localized with membrane HDM-2 exclusively in cancer cells; induced ~100% necrotic cell death (high LDH release, negative caspase markers). Normal colon cells spared. In vivo: tumor nodules underwent necrosis while norm PMID 33419797 Thadi A et al. Anticancer Res. 2021.
  • K562 leukemia cells (p53-null, stem cell-like): strongly express HDM-2 on plasma membrane. PNC-27 co-localized with membrane HDM-2 and achieved ~100% necrotic killing; normal murine lymphocytes spared. Establishes mechanism operates independently of p53 status — membrane-bound HDM-2 is the sole selectivity determinant. PMID 25117093 Davitt K et al. Ann Clin Lab Sci. 2014.
• Pancreatic and ovarian cancer — selective necrosis and paclitaxel synergy Animal studies only
  • Ovarian cancer (ID8 cells): paclitaxel + PNC-27 showed synergistic killing (combination index <1) in vitro. Paclitaxel-surviving cells upregulated surface MDM-2 and showed heightened PNC-27 susceptibility. In vivo: weekly paclitaxel + PNC-27 significantly reduced tumor growth in mice. Demonstrates utility of PNC-27 to PMID 28667027 Alagkiozidis I et al. Ann Clin Lab Sci. 2017.
  • Pancreatic carcinoma MIA-PaCa-2 cells: PNC-27 binds HDM-2 residues 1–109 on membrane (confirmed by antibody blocking). Additionally penetrates cells and accumulates on mitochondrial membranes causing mitochondrial disruption; lysosomes spared. Dual death mechanism: (1) membrane pore formation and (2) intracellular mito PMID 38802154 Krzesaj P et al. Ann Clin Lab Sci. 2024.
• Structural basis of cancer selectivity — NMR conformational studies In vitro only
  • 2D NMR of 32-residue PNC-27: S-shaped three-alpha-helical structure in aqueous solution; U-shaped helix-coil-helix ensemble in membrane-mimetic (organic solvent) conditions. Both environments produce amphipathic organization — hydrophobic residues one face, polar residues opposite. This structural adaptability explains PMID 14967026 Rosal R et al. Biochemistry. 2004.

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

• No human safety data exists. No Phase I trial published in reviewed literature. All cancer selectivity evidence is from in vitro and mouse tumor models. PMID 35625682
• Normal untransformed fibroblasts and murine lymphocytes were spared by PNC-27 in multiple in vitro studies, supporting cancer-selective mechanism based on membrane HDM-2 expression. Absence of in vitro toxicity does not establish in vivo human safety (PMID: 33419797, PMID: 25117093). PMID 33419797
• PNC-27 induces necrosis (not apoptosis) in cancer cells — confirmed by LDH release and negative caspase markers. Necrotic mechanism could elicit inflammatory tumor microenvironment responses in vivo; implications for systemic safety not assessed. PMID 38802154

Contraindications

• No formal contraindications established in reviewed literature. Compound has not been evaluated in human clinical trials. Use outside supervised research settings is not supported by any evidence base. PMID 35625682